Literature DB >> 22581282

Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database study.

Huan Huang1, Jonathan R Korn, Rajiv Mallick, Mark Friedman, Christine Nichols, Joseph Menzin.   

Abstract

Cancer patients, especially those with lung cancer and undergoing chemotherapy, have an elevated risk for venous thromboembolism (VTE). This study assessed incidence, timing, and risk factors for VTE (specifically receipt of chemotherapy), along with the association between VTE and survival among lung cancer patients receiving chemotherapy. Using Florida Medicaid administrative claims data (2000-2008), patients with any diagnosis of primary lung cancer were selected. Patients with recent prior VTE and those enrolled in Medicare or an HMO were excluded. Crude rates of VTE per 100 person years were estimated, and Cox proportional hazards models were developed to assess risk factors for VTE in the lung cancer population, and the association between VTE and survival among patients undergoing chemotherapy. Of 15,749 lung cancer patients, 7,052 (2,242 receiving chemotherapy and 4,810 not receiving chemotherapy) met cohort selection criteria. The incidence of VTE was 10.8 per 100 person-years (PYs) in the chemotherapy cohort and 6.8 per 100 PYs in the non-chemotherapy cohort. Among patients on chemotherapy developing VTE, median time to occurrence was 109 days, with 61 and 82 % of patients experiencing an event within six and 12 months, respectively. In multivariate analyses, the adjusted risk of VTE was 30 % higher among patients undergoing chemotherapy. Comorbidity and the presence of a central venous catheter also were significantly associated with a greater risk of developing VTE. Moreover, patients in the chemotherapy cohort who developed VTE had a significantly faster time-to-death (adjusted hazard ratio [HR] = 1.97; 95 % CI 1.69-2.29).VTE was common among lung cancer patients, especially among patients receiving chemotherapy, with the majority of VTE events occurring within 6 months of initiation of chemotherapy. The presence of a VTE event was significantly associated with an increased risk of mortality.

Entities:  

Mesh:

Year:  2012        PMID: 22581282     DOI: 10.1007/s11239-012-0741-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  33 in total

1.  Impact of venous thromboembolism on survival in patients with malignancy.

Authors:  Shankaranarayana Paneesha; Anand Lokare; Zara Lester; Timothy Nokes; Roopen Arya; Timothy Farren; Nicholas Scriven; Aidan McManus; Denise O'Shaughnessy; Peter Rose
Journal:  Br J Haematol       Date:  2009-02-17       Impact factor: 6.998

2.  Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder.

Authors:  Cheryl S Hankin; Lorrin M Koran; Amy Bronstone; Donald W Black; David V Sheehan; Eric Hollander; Jeffrey D Dunn; Larry Culpepper; John Knispel; Darin D Dougherty; Zhaohui Wang
Journal:  CNS Spectr       Date:  2009-12       Impact factor: 3.790

3.  Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study.

Authors:  Cheryl S Hankin; Linda Cox; David Lang; Amy Bronstone; Paul Fass; Bryan Leatherman; Zhaohui Wang
Journal:  Ann Allergy Asthma Immunol       Date:  2010-01       Impact factor: 6.347

4.  Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.

Authors:  N Levitan; A Dowlati; S C Remick; H I Tahsildar; L D Sivinski; R Beyth; A A Rimm
Journal:  Medicine (Baltimore)       Date:  1999-09       Impact factor: 1.889

5.  Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine.

Authors:  Gianmauro Numico; Ornella Garrone; Vincenzo Dongiovanni; Nicola Silvestris; Ida Colantonio; Gianna Di Costanzo; Cristina Granetto; Marcella Occelli; Elena Fea; Abdelamid Heouaine; Milena Gasco; Marco Merlano
Journal:  Cancer       Date:  2005-03-01       Impact factor: 6.860

6.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

7.  Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.

Authors:  Drew W Rasco; Jingsheng Yan; Yang Xie; Jonathan E Dowell; David E Gerber
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

8.  High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients.

Authors:  Vicky Tagalakis; Dahlia Levi; Jason S Agulnik; Victor Cohen; Goulnar Kasymjanova; David Small
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

9.  Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.

Authors:  Mei Sheng Duh; Jennifer Reynolds Weiner; Patrick Lefebvre; Maureen Neary; Arthur T Skarin
Journal:  Curr Med Res Opin       Date:  2008-02-15       Impact factor: 2.580

10.  Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.

Authors:  Christina Fotopoulou; Andreas duBois; Alexandros N Karavas; Ralf Trappe; Behnaz Aminossadati; Barbara Schmalfeldt; Jacobus Pfisterer; Jalid Sehouli
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

View more
  12 in total

1.  Thromboprophylaxis for lung cancer patients--multimodality assessment of clinician practices, perceptions and decision support tools.

Authors:  M Alexander; S Kirsa; M MacManus; D Ball; B Solomon; K Burbury
Journal:  Support Care Cancer       Date:  2014-02-27       Impact factor: 3.603

2.  Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy.

Authors:  Grzegorz Królczyk; Michał Ząbczyk; Grzegorz Czyżewicz; Krzysztof Plens; Shannon Prior; Saulius Butenas; Anetta Undas
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 3.  Tumor-Derived Apoptotic Vesicles: With Death They Do Part.

Authors:  Morad-Remy Muhsin-Sharafaldine; Alexander D McLellan
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

4.  Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study.

Authors:  Jennifer Howlett; Eric Benzenine; Jonathan Cottenet; Pascal Foucher; Philippe Fagnoni; Catherine Quantin
Journal:  BMC Cancer       Date:  2020-05-24       Impact factor: 4.430

5.  [Perioperative Venous Thromboembolism (VTE) Prophylaxis in Thoracic Cancer Patients: Chinese Experts Consensus - Interpretation of Epidemiological Characteristics].

Authors:  Yixin Sun; Hui Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-12-20

6.  High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations.

Authors:  Yiwei Liu; Wanying Wang; Fengying Wu; Guanghui Gao; Jian Xu; Xuefei Li; Chao Zhao; Shuo Yang; Shiqi Mao; Yingying Pan; Keyi Jia; Chuchu Shao; Bin Chen; Shengxiang Ren; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2021-03

Review 7.  Venous thromboembolism and lung cancer: a review.

Authors:  Carolina Vitale; Maria D'Amato; Paolo Calabrò; Anna Agnese Stanziola; Mauro Mormile; Antonio Molino
Journal:  Multidiscip Respir Med       Date:  2015-09-15

8.  Efficacy and safety of chemotherapy for newly diagnosed advanced non-small cell lung cancer with venous thromboembolism.

Authors:  Xueli Zhang; Huiqiao Li; Wenhui Chen; Yuanhua Yang; Chen Wang; Yuhui Zhang
Journal:  Thorac Cancer       Date:  2015-05-26       Impact factor: 3.500

9.  Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data.

Authors:  Alex J Walker; David R Baldwin; Tim R Card; Helen A Powell; Richard B Hubbard; Matthew J Grainge
Journal:  Br J Cancer       Date:  2016-06-02       Impact factor: 7.640

10.  Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients.

Authors:  Joanna Rupa-Matysek; Marta Lembicz; Eliza Katarzyna Rogowska; Lidia Gil; Mieczysław Komarnicki; Halina Batura-Gabryel
Journal:  Med Oncol       Date:  2018-04-03       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.